Videos

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Suzanne B. Merrill, MD, FACS, discussed the feasibility of integrating immune checkpoint inhibitors into clinical practice for NMIBC, particularly in the community setting.

Freedland reviews enzalutamide’s long-term safety profile, drawing from the EMBARK, ARCHES, and ENZAMET trials. He explains strategies for managing adverse events, balancing efficacy with tolerability, and comparing safety outcomes across other androgen receptor pathway inhibitors to help clinicians personalize care.

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

Ravi D. Chauhan, MD, FACS, outlines the practical considerations for administering nadofaragene in clinical practice.

Panelists discuss how prednisone coadministration with abiraterone impacts tolerability and monitoring in patients with cardiometabolic comorbidities, guiding safer, personalized treatment choices in mCSPC.

Panelists discuss how real-world evidence comparing apalutamide and abiraterone, including the impact of prednisone use, informs balanced and patient-specific first-line treatment choices.

Jonathan Henderson, MD, recaps his LUGPA 2025 session, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.”

Safety outcomes were favorable: cystectomy-free survival was 94%, overall survival was 100%, and only 1 patient progressed to muscle-invasive disease.

Marc Machaalani, MD, shares data on soluble MAdCAM-1 as a predictive biomarker in metastatic renal cell carcinoma.

Panelists discuss how the future of IsoPSA and similar biomarkers depends on data validation, payer support, and integration into clinical guidelines.

Panelists discuss how IsoPSA strengthens biopsy discussions by providing objective data that supports patient confidence in shared decision-making.

The final segment discusses operational and logistical impacts, including workflow efficiency, staff training, and reimbursement considerations for subcutaneous immunotherapy.

Sisters Amy Pearlman, MD, and Michelle Pearlman, MD, provide an overview of their shared practice, Prime Institute.

Ronney Abaza, MD, predicts the transformative impact that AI will have in robotic surgery.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Brooke Edwards, MD, highlights key takeaways from her LUGPA 2025 session, "Transforming your ASC."

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.

Martin M. Miner, MD, highlights key findings from TRAVERSE and the T4DM study.

An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with high-risk T2N0 disease.

Suzanne Merrill, MD, outlines recent progress with immunotherapy across NMIBC and MIBC.

LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting.

This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these findings, how they may alter treatment guidelines, and the importance of counseling asymptomatic patients about the benefits of early systemic therapy.

Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC.

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population.

Panelists discuss how biomarker and molecular testing inform long-term planning in mCSPC, guiding future therapeutic sequencing and improving precision in patient management.

Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy.